|
Short facts |
|
|
Technology |
GAIA´s proprietary artificial intelligence (AI)-expert system, broca® |
|
Indication |
Opioid use disorder (OUD) |
|
Commercial rights |
Orexo owns the global rights |
|
Partner |
GAIA AG |
|
Launch |
To a selected group of clients in late Q4 2020, accelerated launch in H2 2021. Refers to the US market. |
|
Key advantages |
|
Unmet need
The medically assisted treatment of Opioid Use Disorder requires a complete treatment plan, including effective medication, such as Orexo’s commercially available ZUBSOLV®, and counseling and psychosocial support. The access and quality of counseling and psychosocial support remain one of the main barriers to successful treatment in many areas of the US. Orexo believes that the fully-automated digital therapy can become a valuable addition to existing treatment plans, which will improve patients’ access to treatment and overall treatment outcomes.
Related links
About GAIA
The press release communicating the partnership
https://orexo.com/en/media/press-releases?releaseId=B4A65108A4D7F345
Orexo´s CEO gives his remarks to developing a new digital therapy